Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Depreciation & Amortization (CF) of $8.1 million for Q1 2026, up 9.62% year-over-year from $7.4 million in Q1 2025, and little changed quarter-over-quarter from $8.1 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $8.1 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 9.62% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $32.4 million (down 5.1% YoY), while the FY2025 annual figure was $31.6 million, up 12.03% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $8.1 million, roughly flat from $8.1 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $9.8 million in Q3 2024, with the low at $2.7 million in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $7.9 million (2025), against an average of $6.7 million.
- Peak annual rise in Depreciation & Amortization (CF) reached 215.9% in 2024, while the deepest fall reached 24.84% in 2024.
- Amphastar Pharmaceuticals' Depreciation & Amortization (CF) stood at $3.4 million in 2022, then surged by 180.86% to $9.7 million in 2023, then dropped by 24.84% to $7.3 million in 2024, then climbed by 11.22% to $8.1 million in 2025, then gained by 0.09% to $8.1 million in 2026.
- Business Quant data shows AMPH's Depreciation & Amortization (CF) at $8.1 million in Q1 2026, $8.1 million in Q4 2025, and $7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 945.98 Mn | 655.86 Mn | 93.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.04 Mn |
| Jun 30, 2026 | 8.04 Mn |
| Mar 31, 2026 | 8.08 Mn |
| Mar 31, 2026 | 8.08 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Sep 30, 2025 | 7.86 Mn |
| Sep 30, 2025 | 7.86 Mn |
| Jun 30, 2025 | 8.35 Mn |
| Jun 30, 2025 | 8.35 Mn |
| Mar 31, 2025 | 7.37 Mn |
| Mar 31, 2025 | 7.37 Mn |
| Dec 31, 2024 | 7.26 Mn |
| Dec 31, 2024 | 7.26 Mn |
| Sep 30, 2024 | 9.79 Mn |
| Sep 30, 2024 | 9.79 Mn |
| Jun 30, 2024 | 9.68 Mn |
| Jun 30, 2024 | 9.68 Mn |
| Mar 31, 2024 | 9.66 Mn |
| Mar 31, 2024 | 9.66 Mn |